You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
精華製藥(002349.SZ):王氏保赤丸製作技藝入選國家級非遺代表性項目名錄
格隆匯 06-10 15:56

格隆匯6月10日丨精華製藥(002349.SZ)宣佈,近日,國務院發佈了《關於公佈第五批國家級非物質文化遺產代表性項目名錄的通知》(國發〔2021〕8號),國務院批准文化和旅遊部確定的第五批國家級非物質文化遺產代表性項目名錄和國家級非物質文化遺產代表性項目名錄擴展項目名錄。公司申報的“中醫傳統制劑方法(王氏保赤丸製作技藝)被列入國家級非物質文化遺產代表性項目名錄擴展項目名錄,項目編號IX-4。

王氏保赤丸是根據清代南通名醫王臚卿祖傳九世祕方,並由其嫡孫,王氏第19代傳人、首屆國醫大師、中國中醫方劑學創始人、北京中醫藥大學終身教授王綿之先生生前監製的純中藥胃腸動力藥,並被北京大學、美國哈佛醫學中心進一步證實了其能夠調節腸道菌羣、雙向調節胃腸功能。由天津中醫藥大學第一附屬醫院牽頭11家臨牀醫院完成兒童功能性消化不良循證醫學研究;由上海長海醫院李兆申院士團隊牽頭15家臨牀醫院完成王氏保赤丸治療成人功能性消化不良循證醫學研究,循證醫學研究治療效果達到西藥標準品同等效果,且更為安全。

王氏保赤丸臨牀主要用於兒童、成人消化系統和呼吸系統疾病,被列入由中華中醫藥學會主編的《中醫臨牀診療指南釋義》,用於治療兒童小兒厭食症,2018年被列入江蘇省流感診療方案,2020年入選江蘇省中醫藥防治秋冬季疫病的專家共識。該次入選有利於“王氏保赤丸製作技藝”的傳承與傳播,有效保護非物質文化遺產,將進一步奠定公司獨家核心產品王氏保赤丸的優勢地位,對公司產品王氏保赤丸的市場拓展和公司經營業績將帶來積極的影響。

截至目前,公司季德勝蛇藥片、王氏保赤丸均已入選國家級非物質文化遺產名錄,產品品種優勢凸顯,公司將繼續加大核心品種的保護傳承與科研投入,為公司未來發展提供有力保障。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account